Introduction
Methods
Study design and population
Measurements
Statistical analysis
Results
2002 | 2003 | 2004 | 2005 | 2006 |
P for trend | |
---|---|---|---|---|---|---|
N | 522 | 759 | 674 | 1398 | 1484 | |
Age (years) | 69.4 (5.5) | 69.3 (5.6) | 69.3 (5.6) | 68.6 (5.2) | 69.0 (5.8) | |
Men%(n) | 76 (395) | 76 (577) | 79 (532) | 80 (1124) | 78 (1155) | |
High education% (n) | 10 (50) | 12 (93) | 11 (73) | 13 (185) | 13 (196) | |
Time since MI (years) | 5.6 (3.9) | 4.8 (3.1) | 4.1 (2.7) | 4.2 (3.1) | 3.7 (3.0) | |
Prescribed diet% (n) | 12 (61) | 14 (102) | 11 (71) | 10 (145) | 13 (186) | |
Cardiovascular risk factors | ||||||
Current smoking% (n) | 23 (121) | 17 (131) | 18 (121) | 15 (208) | 16 (231) | <0.001a
|
BMI (kg/m2) | 27.9 (3.9) | 28.1 (3.9) | 27.8 (3.9) | 27.6 (3.7) | 27.7 (3.9) | 0.041 |
Obesity%(n) | 27 (141) | 26 (198) | 23 (153) | 23 (326) | 24 (352) | 0.08 |
Waist circumference (cm) | 101.4 (10.5) | 101.3 (10.5) | 101.8 (10.3) | 102.0 (10.3) | 102.5 (10.8) | 0.0096a
|
Central obesity% (n) | 59 (308) | 58 (442) | 60 (407) | 59 (828) | 60 (893) | 0.28 |
Glucose (mmol/l) | 6.07 (2.06) | 6.16 (1.99) | 6.29 (2.27) | 5.98 (2.07) | 6.47 (2.08) | 0.001a
|
Diabetes patients% (n) | 18 (94) | 21 (158) | 24 (165) | 19 (267) | 22 (330) | 0.19 |
Self-reported stroke% (n) | 7 (36) | 9 (67) | 7 (46) | 6 (83) | 8 (113) | 0.86 |
Total cholesterol (mmol/l) | 5.18 (1.05) | 5.09 (0.92) | 4.81 (0.92) | 4.54 (0.91) | 4.51 (0.93) | <0.001a
|
Elevated cholesterol% (n) | 54 (275) | 50 (372) | 35 (233) | 27 (358) | 27 (389) | <0.001a
|
LDL-c (mmol/l) | 3.03 (0.91) | 2.91 (0.80) | 2.72 (0.78) | 2.47 (0.77) | 2.31 (0.77) | <0.001a
|
HDL-c (mmol/l) | 1.27 (0.34) | 1.30 (0.35) | 1.23 (0.33) | 1.24 (0.33) | 1.36 (0.34) | <0.001a
|
Triglycerides (mmol/l)# | 1.69 (1.28, 2.37) | 1.70 (1.27, 2.38) | 1.67 (1.21, 2.31) | 1.62 (1.20, 2.28) | 1.61 (1.18, 2.31) | 0.002a
|
Systolic BP (mmHg) | 143.8 (21.6) | 145.7 (21.9) | 142.8 (21.1) | 140.7 (21.0) | 139.1 (22.0) | <0.001a
|
Diastolic BP (mmHg) | 81.8 (11.3) | 82.2 (11.2) | 80.8 (10.6) | 80.3 (10.8) | 78.1 (11.5) | <0.001a
|
Elevated BP% (n) | 58 (303) | 62 (474) | 55 (372) | 50 (699) | 48 (710) | <0.001a
|
CVD risk factors
Drug treatment
2002 | 2003 | 2004 | 2005 | 2006 |
P for trend | |
---|---|---|---|---|---|---|
Number of patients | 522 | 759 | 674 | 1398 | 1484 | |
Antiplatelet | 81 (424) | 82 (621) | 84 (564) | 85 (1186) | 85 (1255) | 0.035 |
Antithrombotics | 97 (507) | 96 (728) | 98 (661) | 98 (1369) | 98 (1453) | 0.035 |
β-blockers | 54 (281) | 62 (472) | 71 (481) | 71 (995) | 75 (1114) | <0.001a
|
ACE inhibitors | 40 (211) | 40 (305) | 39 (263) | 47 (656) | 43 (631) | 0.043 |
ARBs | 9 (48) | 13 (102) | 15 (101) | 14 (198) | 18 (265) | <0.001a
|
ACEIs and ARBs | 49 (257) | 53 (403) | 53 (354) | 60 (834) | 59 (878) | <0.001a
|
CCBs | 17 (89) | 19 (143) | 26 (172) | 20 (283) | 19 (280) | 0.72 |
Diuretics | 30 (155) | 24 (182) | 24 (160) | 21 (299) | 26 (388) | 0.58 |
All antihypertensive drugs | 82 (430) | 85 (647) | 90 (607) | 91 (1271) | 93 (1385) | <0.001a
|
All lipid-modifying drugs | 74 (384) | 81 (616) | 87 (586) | 89 (1244) | 90 (1331) | <0.001a
|
Insulin | 2 (13) | 5 (36) | 7 (44) | 7 (91) | 6 (89) | 0.004a
|
Biguanides | 5 (24) | 8 (62) | 9 (60) | 8 (118) | 9 (139) | 0.005a
|
Sulphonamides | 9 (49) | 8 (64) | 9 (58) | 7 (91) | 7 (99) | 0.016 |
All antidiabetic drugs | 12 (61) | 15 (116) | 18 (121) | 15 (206) | 16 (236) | 0.11 |
Differences between men and women
Comparison with EUROASPIRE
AOT | AOT | AOT | EUROASPIRE | EUROASPIRE | EUROASPIRE | |
---|---|---|---|---|---|---|
2002 | 2006 | Change from 2002 to 2006 | 1999–2000 | 2006–2007 | Change from 1999 to 2007 | |
N = 522 |
N = 1484 |
N = 1484 |
N = 2975 |
N = 2392 |
N = 2392 | |
Age | 69.4 (5.5) | 69.0 (5.8) | 59.4 (8.5) | 60.9 (7.6) | ||
Male gender | 76% (395/522) | 78% (1155/1484) | 75% (2223/2975) | 77% (1831/2392) | ||
Current smoking | 23% (121/522) | 16% (231/1483) | −7.9% (−12.4, −3.4)a
| 21% (631/2971) | 18% (434/2381) | −1.6% (−5.3, 2.2) |
Obesity | 27% (141/520) | 24% (352/1481) | −3.3% (−8.4, 1.9) | 33% (967/2963) | 38% (902/2376) | 5.5% (−0.1, 11.1) |
Elevated BP | 58% (303/521) | 48% (710/1482) | −10.0% (−16.0, −4.0)a
| 58% (1730/2969) | 61% (1452/2385) | 3.4% (−3.2, 9.9) |
Elevated cholesterol | 54% (275/514) | 27% (389/1438) | −26.3% (−32.0, −20.6)a
| 77% (2122/2766) | 46% (1049/2273) | −32.4% (−39.0, −25.9)a
|
Self-reported diabetes mellitus | 14% (74/519) | 19% (274/1466) | 4.7% (0.07, 9.3)a
| 20% (598/2970) | 28% (664/2371) | 6.4% (1.4, 11.4)a
|
Antiplatelet drugs% | 81% (424/522) | 85% (1255/1484) | 3.1% (−1.4, 7.6) | 84% (2486/2973) | 93% (2214/2376) | 7.1% (4.0, 10.2)a
|
Lipid-modifying drugs% | 74% (384/522) | 90% (1331/1484) | 15.8% (11.7, 20.0)a
| 63% (1864/2973) | 89% (2110/2376) | 23.7% (19.2, 28.1)a
|
β-blockers% | 54% (281/522) | 75% (1114/1484) | 21.2% (15.6, 26.8)a
| 69% (2052/2973) | 86% (2031/2376) | 15.1% (8.5, 21.6)a
|
Antihypertensives% | 82% (430/522) | 93% (1385/1484) | 11.1% (7.4, 14.8)a
| 91% (2694/2973) | 97% (2301/2376) | 5.5% (2.4, 8.5)a
|